Physician profile
Yvette E Newcomb
NPI 1689645814
$4,490.00
in general payments reported to CMS, 2019-2025
32 companies · $1,145 in 2025
The $1,145 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $879 · 2022: $826 · 2023: $1,096 · 2024: $545 · 2025: $1,145.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,598 · Education: $188.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,597.70 |
| Education | $188.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $795.81 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $538.95 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $500.30 | 2021-2025 | |
| Glaxosmithkline, LLC. | $330.52 | 2021-2025 | Trelegy Ellipta, Shingrix |
| Pfizer INC. | $310.84 | 2021-2025 | |
| Astellas Pharma US INC | $271.90 | 2022-2024 | Veozah |
| Xeris Pharmaceuticals, INC. | $192.36 | 2021-2025 | Gvoke Hypopen |
| Lilly USA, LLC | $185.17 | 2021-2025 | Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $146.35 | 2021-2023 | Ofev, Spiriva Respimat, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $142.13 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $132.15 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $119.28 | 2021-2023 | Xarelto |
| Amgen INC. | $108.06 | 2021-2022 | |
| Eisai INC. | $88.67 | 2024-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $85.67 | 2025 | Caplyta |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $78.95 | 2021-2025 | Trintellix |
| Esperion Therapeutics, INC. | $64.40 | 2024-2025 | Nexletol |
| Axsome Therapeutics, INC. | $53.49 | 2024-2025 | Auvelity |
| Amarin Pharma, INC. | $42.29 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $42.22 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $38.09 | 2022 | |
| Merck Sharp & Dohme LLC | $36.28 | 2021 | |
| Optinose US, INC. | $26.55 | 2024 | |
| Abbott Laboratories | $25.26 | 2024 | Freestyle Libre 3 |
| Phathom Pharmaceuticals, INC. | $24.84 | 2025 | Voquezna |
| Dexcom, INC. | $21.57 | 2022 | |
| Dynavax Technologies Corporation | $18.76 | 2024 | Heplisav-B |
| Sumitomo Pharma America, INC. | $16.79 | 2023 | Gemtesa |
| Kowa Pharmaceuticals America, INC. | $14.90 | 2022 | |
| Antares Pharma, INC. | $13.33 | 2022 | |
| Ironwood Pharmaceuticals, INC | $13.08 | 2021 | |
| Mylan Specialty L.P. | $11.04 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yvette Newcomb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.